Vanda Pharmaceuticals | VNDA - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 506.24M 7.31M 2026-03
J&J USD 17.44B 1.53B 2026-03
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.78B 242M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Takeda JPY 1.11T 85.29B 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Veracyte USD 119.99M 3.99M 2026-03